The global next-generation biomanufacturing market is expected to grow at a CAGR of 14.85% during the forecast period 2021-2031 and is expected to reach a value of $85,201.2 million in 2031 – Yahoo Finance

Check back for results at 8:30 a.m. ET
Global Next-Generation Biomanufacturing Market to Reach $85. 20 Billion by 2031. Market Report Coverage – Next-Generation Biomanufacturing Market Segmentation.
New York, Dec. 09, 2021 (GLOBE NEWSWIRE) — announces the release of the report "Next-Generation Biomanufacturing Market – A Global Analysis: Focus on Single-Use and Digital Platform and Segment Analysis for Workflow, Products, Medical Application, End User, Country Data, and Competitive Landscape – Analysis and Forecast, 2020-2031" –

• Workflow – Upstream Biomanufacturing and Downstream Biomanufacturing
• Product – Continuous Upstream Biomanufacturing Products, Single-Use Upstream Biomanufacturing Products, and Downstream Biomanufacturing Products
• Medical Application – Monoclonal Antibodies, Hormones, Vaccines, Recombinant Proteins, Other Applications
• End User – Biopharmaceutical Companies, CMOs/CDMOs, Research Institutions

Regional Segmentation

• North America – U.S. and Canada
• Europe – U.K., Germany, France, Italy, Spain, Ireland, Switzerland, Russia and Rest-of-Europe
• Asia Pacific – China, Japan, India, South Korea, Australia, Singapore and Rest-of-Asia-Pacific
• Latin America – Brazil, Mexico, Argentina and Rest-of-Latin America
• Rest-of-the-World

Market Growth Drivers

• Increasing biologics and biosimilars approvals
• Growing trend among biomanufacturing vendors to integrate automation technologies
• Boosting bioproduction workflow while reducing cost, time, and labor

Market Challenges

• Complex production steps, process operational complexity, risk of product contamination, maintenance of production efficiency, and validation challenges
• Lack of skilled professionals
• Unharmonized manufacturing standards and lack of knowledge and skilled labor in middle-income and low-income countries

Market Opportunities

• Increasing development and commercialization of digital bioreactors
• Increasing Investment in R&D and rapid development of the biopharmaceutical industry

Key Companies Profiled

Applikon Biotechnology BV, bbi-biotech GmbH, Danaher Corporation, Eppendorf AG, Esco Group of Companies, GEA Group Aktiengesellschaft, Meissner Filtration Products, Inc., Merck KGaA, PBS Biotech, Inc., Pierre Guérin, Sartorius AG, Shanghai Bailun Biotechnology Co. Ltd., Solaris Biotechnology Srl., Thermo Fisher Scientific Inc., ZETA GmbH

Key Questions Answered in this Report:
• What are the key trends of the global next-generation biomanufacturing market? How is the market evolving, and what is its future scope?
• What is the role of automation in biomanufacturing?
• What are the major drivers, challenges, and opportunities of the global next-generation biomanufacturing market?
• What is the regulatory framework of the global next-generation biomanufacturing market?
• What is the market share of each of the players offering products for next-generation biomanufacturing? What are the key strategies implemented by the major players to sustain the competition of the global next-generation biomanufacturing market?
• What was the market size of the global next-generation biomanufacturing market in 2020, and what is the anticipated market size in 2031? What is the expected growth rate of the global next-generation biomanufacturing market during the forecast period 2021-2031?
• What are the different next-generation biomanufacturing products used in the medical field? Which product segment is expected to observe the highest CAGR in the market during the forecast period 2021-2031?
• What are the key medical applications of the global next-generation biomanufacturing market? Which application type is expected to witness the highest growth rate during the forecast period of 2021-2031?
• Who are the key end users for the global next-generation biomanufacturing market? What was the market share held by each end user in the global next-generation biomanufacturing market in 2020? What is the expected growth rate and market share by 2031?
• What was the market value of the leading segments and sub-segments of the global next-generation biomanufacturing market in 2020, and what are the values expected to be in 2031? What are the different macro- and micro-economic factors influencing the growth of the market?
• Which region dominated the global next-generation biomanufacturing market in 2020? Which geography can be the target market for significant expansion of key companies for different next-generation biomanufacturing products?
• What are the key countries contributing significantly toward the growth of the next-generation biomanufacturing market?
• What are the key players of the global next-generation biomanufacturing market, and what is their role in the market? Who are the leading payers in the single-use bioreactor market?

Market Overview

Biomanufacturing is the process of production of commercially important biomolecules by utilizing biological systems for use in medicines, food and beverage processing, and industrial applications.Natural sources such as blood, cultures of microbes, animal cells, or plant cells are often employed to carry out biomanufacturing.

Cells used in the production process can also be derived using genetic engineering techniques.

The research study titled “Global Next-Generation Biomanufacturing Market” is focused on understanding the key trends of next-generation biomanufacturing with the use of single-use bioreactors and digital bioreactors across the globe.The research study demonstrates the competitive landscape of the global next-generation biomanufacturing market and presents the market dynamics as well as the regulatory framework affecting the growth of the next-generation biomanufacturing across different regions.

The study also presents an in-depth analysis of the drivers, challenges, and opportunities of the market playing a significant role in major countries of North America, Europe, Asia-Pacific, Latin America, and the Rest-of-the-World.

The report is segmented based on workflow and product, medical application, end user, and region, thoroughly represented in different chapters.Each chapter provides a clear understanding of the products existing in the global next-generation biomanufacturing market and the current key trends in each domain.

The chapter further mentions the key companies of each domain and represents their contribution to the market.The report study also provides a holistic view of 15 major companies playing a key role by contributing their next-generation biomanufacturing market products.

In addition, the report covers detailed information on the advent of automation in biomanufacturing with data on types of automation, current trends, and opportunities in the field of automation.

BIS healthcare experts have found global next-generation biomanufacturing to be one of the most rapidly evolving markets. The global next-generation biomanufacturing market is expected to grow at a CAGR of 14.85% during the forecast period 2021-2031 and is expected to reach a value of $85,201.2 million in 2031.

The following report presents the reader with an opportunity to unlock comprehensive insights regarding the next-generation biomanufacturing market and helps form well-informed strategic decisions. The market research study also offers a broad perspective of the different types of products and services available in the market and their impact on the biomanufacturing industry by providing critical insights into the direction of its future expansion.

Within the research report, the market is segmented based on workflow and product, medical application, end user, and region.Each of these segments has been further categorized into sub-segments to compile an in-depth study.

Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

The global next-generation biomanufacturing market, by workflow, is primarily dominated by upstream biomanufacturing.This is mainly attributed to the involvement of a large number of high-cost equipment in upstream biomanufacturing compared to downstream biomanufacturing.

However, downstream biomanufacturing is expected to witness a high CAGR during the forecast compared to upstream biomanufacturing. This is mainly due to continuous product innovations in the chromatography product lines as well as in filtration systems used in downstream processing.

Among the different regions, North America dominated the global next-generation biomanufacturing market in 2020.Large, well-equipped biomanufacturing facilities with advanced infrastructure and strong investments in the biomanufacturing sector are significantly promoting the growth of the next-generation biomanufacturing market in North America.

Moreover, the ever-expanding biopharmaceuticals and biologics industry in North America is offering huge promises for the industry’s growth, attracting the attention of the investors attempting to enter this field. Further, the headquarters of several key industry players in the U.S., such as Thermo Fisher Scientific, Inc., GE Healthcare, PBS Biotech, Inc., CESCO Bioengineering Co. Ltd., and Meissner Filtration Products, Inc., have further strengthened the market in the region.

Among all the regions, Asia-Pacific is expected to witness the highest CAGR during the forecast period 2021-2031.This is mainly attributed to the strong potential of emerging nations of Asia-Pacific, including Japan, India, Australia, South Korea, and Singapore, that are witnessing huge adoption of technologically advanced biomanufacturing equipment.

The growing surge in new capacity installations to meet the increased product demand in developing nations of Asia-Pacific is further expected to boost the next-generation biomanufacturing market growth.

Competitive Landscape

The next-generation biomanufacturing market is largely dominated by companies such as Applikon Biotechnology BV, bbi-biotech GmbH, Danaher Corporation, Eppendorf AG, Esco Group of Companies, GEA Group Aktiengesellschaft, Meissner Filtration Products, Inc., Merck KGaA, PBS Biotech, Inc., Pierre Guérin, Sartorius AG, Shanghai Bailun Biotechnology Co. Ltd, Solaris Biotechnology Srl, Thermo Fisher Scientific Inc., ZETA GmbH. The bioprocess segment of a few companies like GE Healthcare was highly impacted by the COVID-19 pandemic due to the supply-demand gap. Due to this, the company reported low segment revenue in 2020. However, key players like Danaher Corporation witnessed high growth in the revenue attributed to the high demand for bioprocess solutions products.

The global -next-generation biomanufacturing market is growing exponentially due to the high rate of investments from both public and private sectors for the development of facilities equipped with advanced biomanufacturing equipment and instruments.Automation technologies are increasingly gaining prominence in the biomanufacturing industry over the years owing to their vast range of advantages in terms of greater speed, productivity, and accuracy.

Offering a more streamlined and centralized control, the market for automation systems is growing rapidly, with a greater number of companies investing and launching new automation solutions in the market.

Over the past five years, from 2017 to 2021, the next-generation biomanufacturing market has witnessed around 115 key developments biomanufacturing and automation undertaken by key companies that varied from acquisitions to partnerships and collaborations, among others. For instance, in February 2020, Honeywell International Inc. collaborated with Bigfinite, Inc. to contribute to process automation and controls technology with Bigfinite’s AI, data analytics, and machine learning platform to pace the medical therapies by helping pharma and biotech industries. Further, in March 2019, Rockwell Automation and GE Healthcare underwent a collaborative agreement to combine their automation single-use solution expertise to build bioprocessing operations for digital bioprocessing.

Countries Covered
• North America
• U.S.
• Canada
• Europe
• Germany
• Switzerland
• Ireland
• Italy
• France
• U.K.
• Spain
• Russia
• Rest-of-Europe
• Asia-Pacific
• China
• India
• South Korea
• Japan
• Australia
• Singapore
• Rest-of-Asia-Pacific
• Latin America
• Brazil
• Mexico
• Argentina
• Rest-of-Latin America
• Rest-of-the-World
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.


Fitch Ratings on Thursday lowered the credit rating on embattled home builder China Evergrande to restricted default from C. The downgrades reflect the non-payment of coupons due Nov. 6 for its Tianji subsidiary of $645 million and $590 million after the grace period lapsed on Dec. 6. Fitch said the company did not respond to its request for confirmation on the coupon payments. "Failure to make coupon payments within the grace period is consistent with Fitch's definition of an 'RD' rating, as th
The Dow Jones struggled as the stock market paused. The Donald Trump SPAC rocketed again. Apple stock popped.
Bill Gates looks for income, too. This is how he gets it.
These companies produce the only thing that matters.
Shares of the digital agreement service pioneer DocuSign (NASDAQ: DOCU) recently plunged more than 40% overnight in response to a quarterly earnings report most management teams can only dream of. Results recorded during the company's fiscal third quarter (ended Oct. 31, 2021) were in many ways outstanding. If you're thinking about buying some shares of DocuSign, here's what you should know.
While Nio (NYSE: NIO) shares dropped nearly 20% over the past month, they have been staging a recovery this week. The recent surge in the share price comes as the company's annual Nio Day event approaches, and it has also announced recent progress on its global expansion plans. In fact, the theme for Nio Day is "Hello World," implying the company will update investors further on its growth aspirations outside of China.
The market’s legendary investors built their names, and their fortunes, on success, the paths they followed were as varied and interesting as in any human endeavor. And one of the best such stories for market success is that of Ken Griffin, whose firm Citadel manages approximately $39 billion in total assets. Griffin founded Citadel in 1990, and last year the firm’s funds brought in an average return of 24%. Griffin himself has seen his personal net worth grow to $16 billion. It’s not a bad plac
When the stock market heads south, it's a great time to buy stocks you've long wanted to own.
As of 3:10 p.m. ET Wednesday, shares of hard-hit Chinese education stocks New Oriental Education (NYSE: EDU), Gaotu Techedu (NYSE: GOTU), and TAL Education (NYSE: TAL) are soaring — up 8.3%, 12.2%, and 13.7%, respectively. Ever since the Chinese government announced its crackdown on the for-profit education industry this past summer, New Oriental, Gaotu, and TAL, too, have been in the dumps.
Shares of CVS Health Corp. rose 0.6% in premarket trading Thursday, after the drug store chain and health care services company announced at its Investor Day a $10 billion stock repurchase program, a 10% boost to its dividend and lifted its full-year earnings outlook. The annual dividend rate was raised to $2.20 a share from $2.00 a share, which increases the implied dividend yield at Wednesday's stock closing price to 2.36% from 2.15%, which compares with the implied yield for the S&P 500 of 1.
As 2021 draws to a close, it's a great time to position for the new year — especially given the steep discounts in some tech stocks.
Don't forget what the Federal Reserve is up to, reminds this veteran investing strategist.
Despite the broad-based S&P 500 enduring 38 double-digit percentage corrections since the beginning of 1950, each and every one of these declines was eventually erased by a bull market rally. For the past two weeks, growth stocks with high valuation premiums have been clobbered. Meta's bread and butter has always been social-media platform Facebook, and it will probably remain that way for some years to come.
With the business potentially at an important milestone, we thought we'd take a closer look at Anavex Life Sciences…
GameStop reported earnings on December 8, beating on revenue but missing on other estimates.
Shares of Nuvei Corporation (NASDAQ: NVEI), a payment-processing company, were crumbling today after Spruce Point Capital Management, a short-seller, released a negative report about Nuvei. Spruce Point also said that Nuvei has failed to provide quarterly updates about merchant additions, whether its merchant enterprises are large or small, where sales are occurring geographically, and other details about its sales. Spruce Point said that it estimates up to 40% to 60% long-term downside risk for Nuvei's stock based on its assessment.
Recent weeks have not been kind to DraftKings Inc. (NasdaqGS: DKNG), as the stock suffered through missed earnings and a broad market sell-off that saw the correction of over 30%. Yet, some analysts would argue for 2 cues that predicted this outcome – first, the stock failed to make a new high during the summer and then repeatedly struggled to recapture a critical level of US$50.
(Bloomberg) — An Alibaba Group Holding Ltd.-led effort to take over China’s troubled Tsinghua Unigroup Co. has hit a last-minute snag, according to people familiar with the matter, raising the prospect a rival bidder will close the deal for the semiconductor champion.Most Read from BloombergThe World’s Relentless Demand for Chips Turns Deadly in MalaysiaSand and Soldiers Mix as Troops Move In to Protect Cancun TouristsAnatomy of a Bad RoadThe 15 Best Beers We Drank This YearFormer Oil Trader Is
Shareholders of Decarbonization Plus Acquisition Corp III have approved the merger with EV battery technology start-up Solid Power.
If you are a long-term investor with high-risk tolerance, Roblox (NYSE: RBLX), Skillz (NYSE: SKLZ), and fuboTV (NYSE: FUBO) are three stocks you can buy right now. Roblox is a pioneer of the metaverse, where individuals interact with the environment and each other virtually. Roblox was already growing, but the onset of the coronavirus pandemic caused a surge in engagement.



Add a Comment

Your email address will not be published.